Incyte Corp (LTS:0J9P)
$ 77.12 0.9112 (1.2%) Market Cap: 14.89 Bil Enterprise Value: 13.15 Bil PE Ratio: 552.00 PB Ratio: 4.70 GF Score: 90/100

Incyte Corp at RBC Global Healthcare Conference Transcript

May 19, 2020 / 07:05PM GMT
Release Date Price: $98.05
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good afternoon, everyone. I'm Brian Abrahams, one of the Senior Biotech Analysts here at RBC Capital Markets. It's my pleasure to introduce our next company, Incyte. Representing Incyte will be their Chairman, President and CEO; Hervé Hoppenot; as well as their Executive Vice President and CFO, Christiana Stamoulis. Hervé and Christiana, thanks so much for joining us today.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Thank you. Good afternoon.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Great. So why don't we hop right in? Let's start with Jakafi. It seems like there's been relatively limited impact to the commercial business from the pandemic. And I was wondering if you could maybe talk a little bit about how the dynamics between the MF and PV markets, in particular, have evolved since the pandemic began

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot